title: 3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors.
abstract: The 3-benzimidazol-2-yl-1H-indazole scaffold was developed as an alternate scaffold for our receptor tyrosine kinase (RTK) inhibitor program. In exploring the SAR of this series, it was discovered that a subset of these compounds potently inhibit the enzyme c-ABL. The SAR of these compounds is described.
authors: Small Molecule Drug Discovery, Medicinal Chemistry Department, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA.
authors: Christopher M
authors: CM
authors: McBride
authors: Paul A
authors: PA
authors: Renhowe
authors: Thomas G
authors: TG
authors: Gesner
authors: Johanna M
authors: JM
authors: Jansen
authors: Julie
authors: J
authors: Lin
authors: Sylvia
authors: S
authors: Ma
authors: Yasheen
authors: Y
authors: Zhou
authors: Cynthia M
authors: CM
authors: Shafer